Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133625 · ClinicalTrials.gov registry record · Phase 1
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02133625: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT02133625 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02133625, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
Primary Outcome
To determine the safety, tolerability, and MTD of the combination of pioglitazone (dosed orally once daily at conventional FDA-approved doses) and carboplatin (dosed IV every 3 weeks) in patients with advanced or metastatic solid malignancies. The trial will describe the toxicities of this regimen based on CTCAE. In addition, using RECIST criteria, will look at preliminary anti-tumor activity
Interventions
- DRUG carboplatin
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-08 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What the finished NCT02133625 record still lists
NCT02133625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT02133625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02133625 about?
NCT02133625 is a clinical study titled "A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors". The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
What is the current status of trial NCT02133625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-08. Estimated completion is 2026-01.
What interventions are being tested in trial NCT02133625?
The interventions under investigation include: carboplatin (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT02133625?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02133625's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia